Immunome Raises $27M Via Private Equity Placement At 9%

In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc IMNM has entered into a private placement agreement of approximately $27 million with the sale of 1 million units at $27 per unit.
The offer price is at a 9% discount to Friday's closing price of $29.55.
Each unit consists of one IMNM common share and a warrant to purchase one-half of a common share at an exercise price of $45.
Immunome intends to use the net proceeds to accelerate the development of its oncology and infectious disease portfolio, including COVID-19, and for other general corporate purposes.
Price Action: IMNM shares are trading 8.7% higher at $32.12 in the premarket session on the last check Monday.